Population pharmacokinetics of piperacillin in the early phase of septic shock: does standard dosing result in therapeutic plasma concentrations?

Antimicrobial Agents and Chemotherapy
Kristina Öbrink-HansenJakob Gjedsted

Abstract

Antibiotic dosing in septic shock patients poses a challenge for clinicians due to the pharmacokinetic (PK) variability seen in this patient population. Piperacillin-tazobactam is often used for empirical treatment, and initial appropriate dosing is crucial for reducing mortality. Accordingly, we determined the pharmacokinetic profile of piperacillin (4 g) every 8 h, during the third consecutive dosing interval, in 15 patients treated empirically for septic shock. We developed a population pharmacokinetic model to assess empirical dosing and to simulate alternative dosing regimens and modes of administration. Time above the MIC (T>MIC) predicted for each patient was evaluated against clinical breakpoint MIC for Pseudomonas aeruginosa (16 mg/liter). Pharmacokinetic-pharmacodynamic (PK/PD) targets evaluated were 50% fT>4×MIC and 100% fT>MIC. A population PK model was developed using NONMEM, and data were best described by a two-compartment model. Central and intercompartmental clearances were 3.6 liters/h (relative standard error [RSE], 15.7%) and 6.58 liters/h (RSE, 16.4%), respectively, and central and peripheral volumes were 7.3 liters (RSE, 11.8%) and 3.9 liters (RSE, 9.7%), respectively. Piperacillin plasma concentrations va...Continue Reading

Associated Clinical Trials

Dec 3, 2014·Kristina Öbrink-Hansen, Kristina Öbrink-Hansen

References

Sep 3, 2002·The Journal of Antimicrobial Chemotherapy·Vincent H TamGeorge L Drusano
Dec 31, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Rodger D MacArthurWilliam Barchuk
Sep 24, 2004·Journal of Pharmacokinetics and Pharmacodynamics·Jakob Ribbing, E Niclas Jonsson
Dec 17, 2004·Journal of Veterinary Pharmacology and Therapeutics·P L Toutain, A Bousquet-Mélou
Jan 6, 2007·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Thomas P LodiseGeorge L Drusano
Feb 20, 2007·Antimicrobial Agents and Chemotherapy·Chonghua LiDavid P Nicolau
Jun 6, 2007·Expert Review of Anti-infective Therapy·Alfred GinGeorge G Zhanel
Jul 4, 2008·Critical Care Medicine·Jason A RobertsJeffrey Lipman
Jul 3, 2010·Critical Care : the Official Journal of the Critical Care Forum·Fabio Silvio TacconeFrédérique Jacobs
Aug 6, 2010·International Journal of Antimicrobial Agents·Jason A RobertsJeffrey Lipman
Jan 31, 2013·Intensive Care Medicine·R P DellingerUNKNOWN Surviving Sepsis Campaign Guidelines Committee including The Pediatric Subgroup
Jul 10, 2013·CPT: Pharmacometrics & Systems Pharmacology·R J KeizerA Hooker
Sep 21, 2013·Intensive Care Medicine·Andrew A UdyJeffrey Lipman
Jan 17, 2014·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Jason A RobertsUNKNOWN DALI Study
Jan 21, 2014·The Journal of Antimicrobial Chemotherapy·Gloria WongJason A Roberts
Mar 8, 2014·Diagnostic Microbiology and Infectious Disease·Stijn BlotJason A Roberts
Mar 25, 2014·International Journal of Antimicrobial Agents·Jocelyn TeoAndrea Lay-Hoon Kwa
Apr 23, 2014·Antimicrobial Agents and Chemotherapy·Sangil JeonDong-Seok Yim
Mar 10, 2015·International Journal of Antimicrobial Agents·Jan J De WaeleJason A Roberts
Apr 22, 2015·European Journal of Drug Metabolism and Pharmacokinetics·Rong ChenLi-Ying Wang
Jul 23, 2015·American Journal of Respiratory and Critical Care Medicine·Joel M DulhuntyUNKNOWN BLING II Investigators for the ANZICS Clinical Trials Group *

❮ Previous
Next ❯

Citations

Jun 7, 2016·Critical Care : the Official Journal of the Critical Care Forum·Menino Osbert CottaJeffrey Lipman
May 5, 2016·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·A CharmillonC Pulcini
Nov 8, 2017·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Jeannet C BosJan M Prins
Mar 7, 2018·Antimicrobial Agents and Chemotherapy·Maria Goul AndersenKristina Öbrink-Hansen
Sep 4, 2018·British Journal of Clinical Pharmacology·Dagan O LonsdaleJoseph F Standing
Sep 25, 2018·Critical Care : the Official Journal of the Critical Care Forum·Rui Pedro Veiga, José-Artur Paiva
Apr 10, 2019·Journal of Pharmacokinetics and Pharmacodynamics·Waroonrat SukarnjanasetThitima Wattanavijitkul
Aug 2, 2020·British Journal of Clinical Pharmacology·Agathe BérangerMehdi Oualha
Feb 12, 2021·Clinical Pharmacology and Therapeutics·Cornelia B Landersdorfer, Roger L Nation
Apr 21, 2021·Clinical Pharmacokinetics·Ibrahim El-HaffafAmélie Marsot

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.